Outcome of Board Meeting - In-principle approval of Acquisition
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.2 pts more than Nifty Midcap 150 and 1.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Biocon's Board approved un-audited standalone and consolidated financial results for Q3 and nine months ended December 31, 2025. On a consolidated basis, revenue from operations stood at Rs. 41,730 million, with profit attributable to shareholders of Rs. 1,438 million (EPS of Rs. 1.08), though the reported net loss of Rs. 518 million was driven by a Rs. 1,956 million loss attributable to non-controlling interests. Standalone results showed a net loss of Rs. 764 million, primarily due to exceptional items worth Rs. 1,963 million. The Board also granted in-principle approval to acquire the remaining ~2% stake in Biocon Biologics Limited (BBL) from employees and other shareholders, making BBL a wholly-owned subsidiary. The consideration will be discharged via preferential allotment of Biocon equity shares, subject to shareholder and regulatory approvals. This follows Biocon increasing its stake in BBL to ~98% in January 2026, as part of the full integration plan announced in December 2025.
The acquisition completes Biocon's full integration of its biosimilars business, simplifying the group structure and giving BBL shareholders full economic interest in the subsidiary, though with minor equity dilution for existing Biocon shareholders. The Q3 results show weakness in the standalone entity due to one-time charges, while the biosimilars and CRDMO segments remain profitable, signaling stable core operations.